Revance Therapeutic (RVNC) PT Lowered to $11 at H.C. Wainwright

May 10, 2024 6:55 AM

H.C. Wainwright analyst Douglas Tsao lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $11.00 (from $12.00) while maintaining a Buy rating.

No results found